30
Participants
Start Date
March 26, 2022
Primary Completion Date
December 23, 2024
Study Completion Date
August 15, 2025
Crovalimab
Crovalimab will be administered as a single dose of 1000 milligrams (mg) IV (for participants with a body weight between 40 kilograms (kg) and 100 kg) or 1500 mg IV (for participants with a body weight \>=100 kg).
Placebo
Placebo will be administered as a single IV infusion, with an equal volume and over the same duration as weight- based crovalimab
Charlotte Maxeke Johannesburg Hospital, Johannesburg
Icahn School of Medicine at Mount Sinai, New York
Hospital General Univ. Gregorio Maranon, Madrid
International Cancer Institute (ICI), Eldoret
Children'S Healthcare of Atlanta, Atlanta
Azienda Ospedaliera di Verona-Policlinico G.B. Rossi, Verona
Hospital Universitario Virgen del Rocio, Seville
Hospital Universitario Miguel Servet, Zaragoza
CHU Henri Mondor, Créteil
Hospital Sao Rafael - HSR, Salvador
Hospital das Clinicas - UFRGS, Porto Alegre
Gertrude's Children Hospital, Nairobi
Hopital Nini, Tripoli
American University of Beirut - Medical Center, Beirut
Amsterdam UMC Location VUMC, Amsterdam
Hammersmith Hospital, London
Hoffmann-La Roche
INDUSTRY